A 25+ Year Journey
with a Relentless
Focus on Science

OUR HISTORY

1988

Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College

1989

George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Len Schleifer to launch Regeneron

1990

Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

We announce a collaboration to develop neurotrophic factors

1991

REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

1992

Clinical development of our first investigational drug, a neurotrophic factor, begins

1993

We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

1995

Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

1997

The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

1999

George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

2000

ARCALYST® (rilonacept) Injection, our first Trap technology, begins clinical exploration

2003

Our first paper on VelociGene® is published, introducing the world to our proprietary Veloci technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

2004

EYLEA® (aflibercept) Injection begins clinical development

2006

A collaboration with Bayer HealthCare focuses on developing EYLEA® (aflibercept) Injection outside the U.S.

Sarilumab, our first fully human antibody, enters clinical development

2007

A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune® technology platform

2008

The FDA approves our first medicine, ARCALYST® (rilonacept) Injection

2009

We expand and extend our antibody collaboration with Sanofi

PRALUENT® (alirocumab) Injection begins clinical development

We hire our 1,000th employee and move into new buildings on our Tarrytown campus

2010

We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

2011

The FDA approves EYLEA® (aflibercept) Injection for its first indication

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®

2012

The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

2013

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

Our European business office opens in Dublin, Ireland

Scrip Intelligence names Len and George as the "Management Team of the Year"

2014

The Regeneron Genetics Center, a new human genetics initiative, officially launches

The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

We begin building our first ex-U.S. IOPS site in Limerick, Ireland

2015

The FDA approves PRALUENT® (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immuno-oncology collaboration with Sanofi

We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

2016

We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

2017

The FDA approves DUPIXENT® (alirocumab) Injection, our fifth FDA-approved medicine

OUR HISTORY

1988

Regeneron is founded by Leonard S. Schleifer, MD, PhD, young neurologist and assistant professor at Cornell University Medical College

1989

George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Len Schleifer to launch Regeneron

1990

Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

We announce collaboration to develop neurotrophic factors

1991

REGN stock begins trading publicly on the NASDAQ; the Initial Public Offering raises $91.6 million

1992

Clinical development of our first investigational drug, a neurotrophic factor, begins

1993

We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved product

1995

Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

1997

The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

1999

George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

2000

ARCALYST® (rilonacept) Injection, our first Trap technology, begins clinical exploration

2003

Our first paper on VelociGene® is published, introducing the world to our proprietary Veloci technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

2004

EYLEA® (aflibercept) Injection begins clinical development

2006

A collaboration with Bayer HealthCare focuses on developing EYLEA® (aflibercept) Injection outside the U.S.

Sarilumab, our first fully human antibody, enters clinical development

2007

A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune® technology platform

2008

The FDA approves our first medicine, ARCALYST® (rilonacept) Injection

2009

We expand and extend our antibody collaboration with Sanofi

PRALUENT® (alirocumab) Injection begins clinical development

We hire our 1,000th employee and move into new buildings on our Tarrytown campus

2010

We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

2011

The FDA approves EYLEA® (aflibercept) Injection for its first indication

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®

2012

The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

2013

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

Our European business office opens in Dublin, Ireland

Scrip Intelligence names Len and George as the "Management Team of the Year"

2014

The Regeneron Genetics Center, a new human genetics initiative, officially launches

The FDA grants investigational antibody dupilumab Breakthrough Therapy designation

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields

We begin building our first ex-U.S. IOPS site in Limerick, Ireland

2015

The FDA approves PRALUENT® (alirocumab) Injection, our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immuno-oncology collaboration with Sanofi

We enter into an agreement with the U.S. government for the development of a new antibody treatment for the Ebola virus

2016

We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

2017

lorem ipsum

NOW APPROVED IN THE UNITED STATES

Learn more